Quincy Sous Senart

This observational study evaluates the Polymer Free Sirolimus Eluting Coronary Stent System, known as the Vivo ISAR, in everyday clinical practice for patients with coronary artery stenosis. The purpose is to collect real-world data on clinical outcomes over a 12-month follow-up period, focusing on patients who receive this stent system as part of their routine care. The study is sponsored by Translumina GmbH and involves standard procedures and medications with known safety profiles. Participants will be treated with the Vivo ISAR stent during percutaneous coronary intervention to improve coronary artery diameter in those experiencing symptoms of ischemic heart disease. The study monitors patients who receive the stent in one or multiple vessels, observing their progress without altering standard care practices. The follow-up extends to 12 months after the procedure to assess various success rates and treatment effects. During the study, participants undergo routine clinical evaluations including assessments of device and procedural success shortly after treatment, and measures of target lesion failure and reperfusion at 12 months. Researchers also evaluate antiplatelet therapy adherence and effectiveness. The total participation involves regular check-ups and data collection to understand long-term outcomes and safety of the Vivo ISAR stent system in typical healthcare settings.

This research aims to evaluate how often diaphragmatic dysfunction occurs after non-intubated video-assisted thoracoscopic surgery NIVATS. This surgery is typically used for wedge resections, pneumothorax repair, and pleural biopsies, sometimes with talc pleurodesis for pleural effusion. The study is prospective and longitudinal, conducted at a single center to closely monitor patients undergoing this procedure. Participants will undergo NIVATS, which is considered the least invasive surgical approach and is part of an enhanced recovery pathway. Evaluations will take place during surgery, then again at 2 hours and 24 hours after surgery. Data from these assessments will be recorded electronically by physicians. During the study, participants will be evaluated multiple times to assess diaphragmatic movement and thickness as well as pain and any postoperative complications. The main measurement is diaphragmatic excursion 24 hours after surgery, with additional assessments at 2 and 24 hours post-surgery. The study will continue until February 2027, involving ongoing monitoring and data collection.

Researchers are comparing two pain relief methods for people undergoing total knee arthroplasty, commonly known as knee replacement surgery, due to gonarthrosis. The study evaluates whether a new quadruple peripheral nerve block provides better pain control than the current standard procedure, which combines an adductor canal block with surgical infiltration. The goal is to understand which approach improves patient recovery after surgery.

Researchers are collecting detailed data on adults experiencing convulsive and non-convulsive status epilepticus SE or pseudo status epilepticus. This observational study aims to understand the circumstances, treatment, and outcomes of SE in critically ill patients by gathering extensive clinical and demographic information. The study is sponsored by the Ictal Group and tracks patient progress up to one year after SE onset. Participants with SE are observed without intervention, focusing on data collection such as seizure onset, treatment timing, EEG monitoring results, and seizure characteristics. The study includes both convulsive and non-convulsive SE cases, as well as pseudo SE, using standardized forms to document pre-hospital and hospital care details. Outcome evaluations are scheduled at ICU and hospital discharge, and follow-ups occur at 90 days and one year after SE. During the study, participants vital status and neurological outcomes are assessed using the Glasgow Outcome Scale at multiple timepoints. Researchers also monitor seizure recurrence, total seizure duration, and length of hospital stay. The study tracks mortality rates at ICU and hospital discharge and up to ten years in secondary measures. Data collection includes patient chart reviews and phone interviews to ensure comprehensive follow-up over time.

Researchers are studying how iron is absorbed, metabolized, eliminated, and stored in the body during advanced kidney failure. The focus is on understanding how hormones that regulate iron interact with calcium, phosphate, liver metabolism, and inflammation in patients undergoing hemodialysis. The main goal is to monitor the levels of two key biomarkers, hepcidin and erythroferrone, which are important in iron metabolism but not routinely measured in dialysis centers. This observational study involves hemodialysis patients who will have blood samples taken to track changes in hepcidin and erythroferrone levels over time. Each blood draw collects 15 mL to measure these markers. The study does not involve any treatment but observes the natural progression and relationships between iron metabolism and other body processes in these patients. Participants will be followed for five years, during which the concentration of hepcidin and erythroferrone will be regularly measured through blood tests. The study will also consider links with calcium phosphate metabolism, liver function, and inflammation. Patients will provide written consent and undergo periodic assessments to help researchers understand how these markers evolve in the context of hemodialysis and related complications.

Researchers are investigating kidney cancer through the UroCCR network, a national registry and research platform in France that collects detailed real-world data on patient care and disease progression. Established in 2011, this extensive database includes over 21,000 cases from 58 centers and links clinical information with annotated biological samples and national health data. The platform supports multiple types of research, including translational studies, clinical evaluations, and social science investigations, aiming to improve understanding and management of renal cell carcinoma. The study involves adult patients diagnosed with kidney cancer and documents their treatments, including procedures such as radical or partial nephrectomy as determined by the surgeon. Data collected encompasses clinical parameters, imaging, patient-reported outcomes, and socioeconomic factors. The registry supports prospective research projects and ancillary studies, with a focus on real-world practice following national guidelines. It also integrates digital tools for monitoring and prediction, enhancing personalized treatment strategies. Participants contribute data continuously from enrollment through long-term follow-up, which may last until death or withdrawal. The study collects comprehensive clinical, biological, imaging, and patient-reported information, along with biological samples like plasma, urine, and tumor tissue. Researchers measure outcomes related to research project promotion, biological sample collection, epidemiology, treatment monitoring, quality of life, biomarker research, and clinical practice evaluation. This ongoing data collection supports knowledge advancement and improved kidney cancer care over many years.